SCHEMBL3015940

SCHEMBL3015940

COc1ccc(OC)c(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)c(F)c4)cs3)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 3/20 0.48
RECQL P46063 2/20 0.48
LMNA P02545 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
USP2 O75604 2/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 1/20 0.47
CCR3 P51677 2/20 0.46
CCR5 P51681 1/20 0.44
TSHR P16473 3/20 0.44
HSD17B10 Q99714 3/20 0.44
MAPK1 P28482 1/20 0.43
HPGD P15428 1/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3648489 0.94 ALDH1A1 (0.43) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3013023 0.93 MAPT (0.44) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3015495 0.93 ALDH1A1 (0.48) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3015488 0.93 ALDH1A1 (0.50) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3002880 0.92 LMNA (0.53) ALDH1A1KMT2AMAPTLMNAL3MBTL1
SCHEMBL3014635 0.92 ALDH1A1 (0.51) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3006711 0.91 GAA (0.47) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3018100 0.90 ALDH1A1 (0.52) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3008781 0.90 ALDH1A1 (0.53) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3002250 0.90 ALDH1A1 (0.55) ALDH1A1KMT2AMAPTRECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885KMT2A 2680/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.